Global Intravenous Immunoglobulin Market

Intravenous Immunoglobulin Market Size, Share, Growth Analysis, By Application(Hypogammaglobulinemia, CIDP, Immunodeficiency Diseases, Congenital AIDS), By Type(IgG, IgM, IgA, IgE), By Distribution Channel(Hospital Pharmacy, Specialty Pharmacy, and Others), By Region - Industry Forecast 2025-2032


Report ID: SQMIG35A2611 | Region: Global | Published Date: February, 2024
Pages: 157 | Tables: 100 | Figures: 69

Intravenous Immunoglobulin Market Dynamics

Drivers

Increasing Adoption of Intravenous Immunoglobulins to Drive Market Growth

  • The pervasive uptake of intravenous immunoglobulin therapy as the foremost treatment avenue for numerous rare immunological and neurological conditions, notably primary immunodeficiency (PI) and associated diseases, emerges as a cornerstone propelling the expansion of the intravenous immunoglobulin market. This extensive acceptance of IVIG therapy as the frontline treatment signifies its efficacy and relevance in managing these conditions effectively.

Restraints

High Cost of Treatment to Impede Market Growth

  • The diagnosis and treatment expenses associated with demyelinating diseases present a considerable financial burden. The rising costs linked to IVIG therapy stand out as a significant barrier to the market's expansion. Typically administered every 3 to 4 weeks, IVIG infusions are recurrent, involving approximately 12 to 16 sessions annually. The projected cost of IVIG is estimated at USD 73.89 per gram, amounting to a total expense of around USD 10,000.
$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Intravenous Immunoglobulin Market size was valued at USD 11.98 billion in 2022 and is poised to grow from USD 12.9 billion in 2023 to USD 22.6 billion by 2031, growing at a CAGR of 7.3% in the forecast period (2024-2031).

The competitive environment of the global Intravenous Immunoglobulin Market is dynamic and characterized by the presence of a mix of well-established brands, emerging players, and niche producers. Innovation is a key competitive factor. Leading brands invest in research and development to introduce new flavors, packaging formats, and health-focused variations to cater to changing consumer preferences. They often set the trends in the industry. 'Grifols SA', 'Octapharma AG', 'ADMA Biologics', 'LFB Biotechnologies', 'Kedrion Biopharma', 'Intas Pharmaceuticals', 'Biotest AG', 'BDI Pharma Inc.', 'Shanghai RAAS Blood Products Co., Ltd.', 'Takeda Pharmaceutical Company Limited.', 'CSL Behring', 'Baxter International Inc.', 'China Biologics Products Inc.'

The pervasive uptake of intravenous immunoglobulin therapy as the foremost treatment avenue for numerous rare immunological and neurological conditions, notably primary immunodeficiency (PI) and associated diseases, emerges as a cornerstone propelling the expansion of the intravenous immunoglobulin market. This extensive acceptance of IVIG therapy as the frontline treatment signifies its efficacy and relevance in managing these conditions effectively.

The market's evolution is being driven by several impactful trends that are reshaping its trajectory for growth and progress. Notably, the rising use of Intravenous Immunoglobulin (IVIG) in treating neurological disorders marks a significant trend, highlighting its expanding application beyond traditional uses. Additionally, the integration of personalized medicine principles into IVIG therapy represents a notable shift, tailoring treatments to individual patient needs. The emergence of novel immunomodulatory treatments is also shaping the landscape, offering innovative therapeutic avenues.

In 2022, North America emerged as the leading force within the market, securing a commanding revenue share of 46.51%. The region's dominance stems from several pivotal factors fostering its market growth. Notably, there has been a substantial uptick in awareness regarding products designed to address immunodeficiency diseases, fostering a deeper understanding among both healthcare professionals and the general populace.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Intravenous Immunoglobulin Market

Report ID: SQMIG35A2611

$5,300
BUY NOW GET FREE SAMPLE